RxDoctor Payments Data

Andrew Wiele, DO

Hematology & Oncology · Elmhurst, ILNPI 1447663539

Payments from drug & device makers

$55,452in general payments, 2019–2025

Across 63 payments — averaging $880.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$54K
  • Intera Oncology, Inc$242
  • Novartis$187
  • Merck$134
  • Pfizer$94
  • E.r. Squibb & Sons, L.L.C.$88
  • plus $579 from 15 others

What the payments were for

  • Food & beverage$1,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,452 in reported general payments places this provider in the 65th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$184,047
Medicare patients
372
Services billed
2,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate13$331,805
ErleadaApalutamide16$237,754
XtandiEnzalutamide17$237,410
BrukinsaZanubrutinib11$167,052
EliquisApixaban70$58,471
Abiraterone Acetate36$48,424
XareltoRivaroxaban31$32,831
Gabapentin11$631
Hydroxyurea22$579
Pantoprazole Sodium14$321
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$319
Potassium Chloride15$191
Prochlorperazine Maleate12$179
Triamcinolone Acetonide13$172
Mirtazapine19$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$48$237,41017 claims
PfizerEliquis$94$58,47170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Elmhurst

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →